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Abstract
Background: Cervical artery dissection (CeAD) patients with or without stroke
are frequently treated with either antiplatelet agents or vitamin K antagonists
(VKAs), but few data are reported on the use of nonvitamin K oral anticoagu-
lants (NOACs). Methods: Between November 2011 and January 2014, we
recorded data from patients with a stroke due to vertebral (VAD) or internal
carotid artery dissection (ICAD). Patients using oral anticoagulants were
included in the study and were divided into two treatment groups: patients
using NOACs and those using VKAs. Excellent outcome was defined on modi-
fied Rankin Scale (mRS) ≤1 at 6 months. Results: Of 68 stroke patients (67%
male; median age 45 [39–53]), six (8.8%; two with VAD and four with ICAD)
were treated with NOACs: three with direct thrombin inhibitor dabigatran and
three with direct factor Xa inhibitor rivaroxaban. National Institutes of Health
Stroke Scale score at baseline was 4 (3–7) in the NOAC versus 2 (1–7) in the
VKA groups. Complete recanalization at 6 months was seen in most patients in
the NOAC (n = 5; 83%) and VKA (n = 34; 55%) groups. All the patients using
NOACs had mRS ≤1 at 6 months and none had an intracerebral hemorrhage
(ICH). In the VKA group most patients (n = 48; 77%) had mRS ≤1, one
patient (1.7%) had an ICH and one died. Conclusions: In this small, consecu-
tive single-center patient sample treating ischemic stroke patients with CeAD
with NOACs did not bring up safety concerns and resulted in similar, good
outcomes compared to patients using VKAs.
Background
Cervical arterial dissections (CeAD), that is, vertebral
artery (VAD) and internal carotid artery (ICAD) dissec-
tions are common etiologies of ischemic stroke in the
young (Yesilot Barlas et al. 2013). Early treatment is cru-
cial as it can prevent vessel occlusion or embolic sequels
and avoid serious neurologic deficits. Most physicians
prescribe anticoagulants for stroke prevention in acute
CeAD, although there are no randomized trials compar-
ing the safety and efficacy of anticoagulants with antiplat-
elets or placebo (Engelter et al. 2007; Sarikaya et al.
2013).
Anticoagulation with nonvitamin K oral anticoagulants
(NOACs) is increasingly used for stroke prevention in
patients with atrial fibrillation (AF), instead of vitamin K
antagonists (VKAs), as both direct factor Xa (Granger
et al. 2011; Patel et al. 2011) and direct thrombin
(Connolly et al. 2009) inhibitors have been shown to have
similar or better safety and efficacy profiles compared
with warfarin. There is few data on their use in ischemic
stroke patients with CeAD (Caprio et al. 2014); and only
one report was found with 10 stroke patients using
NOACs as the secondary prevention of ischemic stroke.
Methods
Between November 2011 and January 2014 we recorded
data from consecutive patients with a stroke due to VAD
or ICAD. This study was approved by our institutional
authorities. Our institutional guidelines recommend the
use of anticoagulants in all CeAD patients for 6 months,
and the selection of the anticoagulant is decided by the
treating neurologist together with the patient.
Patients using oral anticoagulation were included in the
study and were divided into two groups: patients using
NOACs, and those using VKAs. Patients who underwent
endovascular stenting followed by antiplatelet therapy,
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and patients treated with only heparin or LMWH were
excluded. We excluded two patients with multiple trau-
matic injuries not receiving oral anticoagulation to keep
the study population homongenous.
Recurrent ischemic stroke, or intracerebral hemorrhagic
(ICH) stroke events, recanalization rate, and functional
outcome on the modified Rankin Scale (mRS) within six
months were evaluated and compared between the NOAC
and VKA-treated groups. An excellent outcome was
defined as mRS≤1 at 6 months.
Statistical analyses
Statistical significance for intergroup differences was
assessed by Chi-square test for categorical variables, and
Mann–Whitney U-test for noncontinuous variables or
skewed numerical variables. Statistical significance was set
at <0.05. Analyses were performed with SPSS 19 (SPSS
Inc., Chicago, IL, USA).
Results
Of 68 stroke patients included (Table 1), six were treated
with NOACs (three with dabigatran and three with riva-
roxaban) and 62 with warfarin. There were slightly more
men and VAD was seen in most patients (Table 2). There
were no statistical differences between the two groups in
stroke severity, recanalization rate, or outcome
(P > 0.05). All the patients using NOACs had mRS ≤1
with no bleeding complications, or recurrent dissections.
Discussion
Stroke is the most common complication of CeAD, occur-
ring in two thirds of the cases (Lichy et al. 2012). Although
the molecular mechanisms are still poorly understood in
CeAD (Debette 2014), imaging studies and transcranial
ultrasound have suggested that arterial embolism is the
main mechanism of stroke (Benninger et al. 2004), explain-
Table 1. Baseline characteristics and outcome in cervical arterial dis-
section patients with acute stroke using nonvitamin K oral anticoagu-
lants or vitamin K antagonists.
NOAC
(n = 6; 8.8%)
VKA
(n = 62; 91%)
All
(n = 68)
Age, median (IQR) 44 (38–46) 46 (39–53) 45 (39–53)
Male gender 4 (67) 39 (63) 43 (63)
NIHSS at baseline 4 (2–5) 2 (1–7) 2 (1–6)
Vertebral artery
dissection
2 (33) 38 (61) 40 (59)
Occlusion 1 (33) 15 (40) 16 (39)
Stenosis 2 (67) 23 (60) 25 (61)
Internal carotid artery
dissection
4 (67) 27 (44) 31 (46)
Occlusion 1 (33) 14 (52) 15 (50)
Stenosis 2 (67) 13 (48) 15 (50)
Symptom onset to
hospital
0.5 (0–4.0) 0.5 (0–1.3) 0.5 (0–1.8)
Prior infection 3 (50) 7 (11) 10 (15)
Prior trauma 0 16 (26) 16 (24)
Recanalization 5 (83) 34 (55) 39 (57)
Modified Rankin
Scale ≤ 1
6 (100) 48 (77) 54 (79)
Intracerebral
hemorrhage
0 1 (1.6) 1 (1.5)
Death 0 1 (1.6) 1 (1.5)
Values are median (interquartile range) and n (%). NOAC, nonvitamin
K oral anticoagulants; VKA, vitamin K antagonists; NIHSS, National
Institutes of Health Stroke Scale. Data on recent infection within
1 week and trauma, physical impact on the head or neck within
1 month were obtained from the patient records.
Table 2. Clinical, radiological, and outcome data in six stroke patients with cervical arterial dissection using nonvitamin K oral anticoagulants.
Patient/Age1/Gender
Baseline
NIHSS
Baseline
MRA
Recanalization
at 6 months
mRS at 6
months
VAD
1/32/M 2 Intramural hematoma Yes 0
2/45/M 3 Flame-shaped proximal occlusion No 0
3/42/M 4 High grade string-like stenosis Yes 1
ICAD
4/45/M 6 Intimal flap with proximal occlusion Yes 0
5/40/M 4 Intramural hematoma and intimal flap
with high grade stenosis
Yes 0
6/47/F 1 Intramural hematoma, and intimal flap
with high grade stenosis
Yes 0
NIHSS, National Institutes of Health Stroke Scale; MRA, magnetic resonance angiography; mRS, modified Rankin Scale; VAD, vertebral artery dis-
section; ICAD, internal carotid artery dissection; M, male, F, female.
1Years.
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ing why anticoagulation is frequently used. ICH is the most
feared and serious complication of the use of oral anticoag-
ulation in the prevention and treatment of strokes. In a
meta-analysis it was recently concluded that instead of anti-
coagulants antiplatelets should be used because they cause
less bleeding events (Sarikaya et al. 2013), despite a trend
was seen during the first week toward more deaths in the
antiplatelet group (Sarikaya et al. 2013).
An excellent outcome was seen in all of our patients in
the NOAC group and 77% in the VKA group. In a recent
report on NOACs and CeAD, there were more recurrent
strokes and radiographic progression of dissection while
bleeding complications were less common (Caprio et al.
2014). In our study group, only one death and one seri-
ous ICH occurred during the 6-month treatment period,
both in the VKA group. Fewer bleeding complications
have been seen with the NOACs in stroke prevention in
AF in three randomized trials (Connolly et al. 2009;
Granger et al. 2011; Patel et al. 2011) and the European
Society of Cardiology recommends NOACs in preference
to VKA therapy for stroke prevention in patients with
AF. In the first report with NOACs and CeAD, there were
no major bleeds and 5% minor hemorrhagic complica-
tions being equal to the rate in the antiplatelet group
(Caprio et al. 2014). We anticipate that the indications
for the use of NOACs will be extended over time, when
new data on their use in different conditions have accu-
mulated. Recently, another off-label indication for using
NOACs was reported, as factor Xa inhibitors showed a
similar clinical benefit as VKAs in the treatment of cere-
bral venous thrombosis in a small study cohort of seven
patients (Geisbusch et al. 2014).
CeAD etiology dominates in the younger age groups
(Metso et al. 2012), unlike AF with a higher risk for
bleeding complications associated with older age
(Pancholy et al. 2014). The NOAC plasma concentra-
tions achieved with a given dose vary, depending on
absorption, renal function, and other factors that can be
problematic with the elderly (Reilly et al. 2014). In the
young and socially active CeAD patients, at least those
with less severe strokes, many could benefit of NOACs
given as a fixed dose without laboratory monitoring.
Currently it remains unknown whether there is a single
concentration range, where the balance between
thrombo-embolic events and bleeding events is optimal
for CeAD patients. It could be, however, that in more
stable CeAD stroke patients the concentration range can
be wider, and that NOACs could serve as a first-line
treatment for the relatively short treatment period used
in CeAD.
Our study has limitations. It is retrospective, and the
number of patients treated with NOACs is small. As there
are no randomized controlled trials going on, it adds new
information on safety issues on secondary prevention
with NOACs in stroke patients with CeAD.
Conclusion
In this small, consecutive single-center patient sample
treating ischemic stroke patients with CeAD with NOACs
did not bring up safety concerns and resulted in similar,
good outcomes compared to patients using VKAs.
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